BioCryst Pharmaceuticals (BCRX) Q3 2024 earnings summary

Executive summary

• ORLADEYO revenue reached $116.3 million in Q3 2024, up 35.7% year-over-year, driving total quarterly revenue to $117.1 million and full-year guidance to $430–$435 million.

• Achieved GAAP operating profit of $7.7 million and non-GAAP operating profit of $24.9 million for the second consecutive quarter, with net loss narrowing to $14.0 million.

• Advanced pipeline with BCX17725 entering clinical trials for Netherton syndrome and avoralstat for diabetic macular edema, both expected to dose patients in 2025.

• Strong real-world evidence supports ORLADEYO's efficacy, high adherence, and commercial momentum, with global expansion ongoing.

• Secured a $69 million U.S. government contract for RAPIVAB, with the first $13.9 million order to be fulfilled by September 2025.

Financial highlights

• Q3 2024 total revenue was $117.1 million, with $116.3 million from ORLADEYO and $13.2 million from ex-U.S. sales.

• Operating expenses (excluding non-cash stock comp) were $92.2 million; GAAP OpEx was $109.4 million; full-year 2024 OpEx guided at $380–$390 million.

• Cash, cash equivalents, and investments at quarter end totaled $351.7 million.

• Operating cash increased by $13.1 million in Q3 2024.

• Interest expense for Q3 2024 was $24.8 million, down from $27.3 million in Q3 2023.

Outlook and guidance

• 2024 ORLADEYO revenue guidance set at $430–$435 million, with total company revenue guidance at $443–$448 million including RAPIVAB.

• Full-year 2024 operating profit (excluding stock comp) expected, with positive EPS and cash flow targeted in 2025 and full-year profitability in 2026 without new funding.

• Projecting compound annual global revenue growth of nearly 20% through 2029, targeting $1 billion in annual revenue.

• Financial resources expected to fund operations for at least the next 12 months.

• No immediate plans to access capital markets; additional funding options are regularly evaluated.